Michael Hammer, Bernd Echtenachter, Heike Weighardt, Katrin Jozefowski, Stefan Rose-John, Daniela N Männel, Bernhard Holzmann, Roland Lang
The mitogen-activated protein kinase phosphatase Dusp1 (also known as MKP-1) is essential for control of the inflammatory response to systemic challenge with the lipopolysaccharide of Gram-negative bacteria. Here, we have investigated the consequences of Dusp1-deficiency in colon ascendens stent peritonitis (CASP) and caecal ligation and puncture (CLP), two mouse models of septic peritonitis. Following CASP, Dusp1(-/-) mice had increased serum levels of CCL4, interleukin-10 (IL-10) and IL-6, with differences from wild-type mice being dependent on severity of sepsis. These cytokines, along with inducible nitric oxide synthase messenger RNA, were also expressed at higher levels in spleen and liver. Similar over-production of these cytokines was detected in the CLP model, with even larger differences from wild-type mice. Despite the increased inflammatory response, bacterial clearance was impaired in Dusp1(-/-) mice subjected to CASP and CLP. Dusp1(-/-) mice suffered increased lethality in both peritonitis models. Together our data indicate that exaggerated inflammatory responses to gut bacteria introduced into the peritoneum in the absence of Dusp1 do not help to control bacterial replication but are detrimental for the host.
J Leukoc Biol. 2008 Apr;83(4):1009-18
[PMID:
18211965]
J Immunol. 2009 Jul 15;183(2):1197-206
[PMID:
19542371]
J Immunol. 2009 Dec 1;183(11):7411-9
[PMID:
19890037]
Eur Cytokine Netw. 2001 Oct-Dec;12(4):581-6
[PMID:
11781184]
J Inflamm. 1995-1996;47(1-2):85-9
[PMID:
8913934]
J Immunol. 2001 Oct 1;167(7):3919-27
[PMID:
11564810]
Nat Rev Drug Discov. 2007 May;6(5):391-403
[PMID:
17473844]
J Immunol. 1990 Dec 1;145(11):3762-6
[PMID:
2246512]
Ann Surg. 2005 Dec;242(6):830-8, discussion 838-9
[PMID:
16327493]
J Exp Med. 2006 Jan 23;203(1):15-20
[PMID:
16380512]
Nat Rev Drug Discov. 2005 Oct;4(10):854-65
[PMID:
16224456]
Shock. 2004 Jun;21(6):505-11
[PMID:
15167678]
J Immunol. 2003 Sep 15;171(6):3202-9
[PMID:
12960349]
J Immunol. 2001 Jan 1;166(1):582-7
[PMID:
11123340]
J Immunol. 1995 Dec 1;155(11):5397-401
[PMID:
7594556]
J Immunol. 2006 Feb 1;176(3):1899-907
[PMID:
16424221]
Infect Immun. 2001 Jun;69(6):3550-5
[PMID:
11349012]
Infect Immun. 2005 May;73(5):2751-7
[PMID:
15845478]
J Leukoc Biol. 2006 Aug;80(2):227-36
[PMID:
16707558]
Nature. 1996 May 2;381(6577):75-7
[PMID:
8609992]
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2274-9
[PMID:
16461893]
J Immunol. 2008 Oct 15;181(8):5598-605
[PMID:
18832718]
Infect Immun. 2001 Dec;69(12):7271-6
[PMID:
11705897]
J Immunol. 1997 Apr 15;158(8):3971-7
[PMID:
9103468]
Int Immunol. 2005 Aug;17(8):1035-46
[PMID:
16000329]
J Immunol. 2006 Dec 1;177(11):7497-504
[PMID:
17114416]
Infect Immun. 1998 May;66(5):2300-9
[PMID:
9573121]
Oncogene. 1996 Sep 5;13(5):925-31
[PMID:
8806681]
J Immunol. 2002 Sep 15;169(6):2823-7
[PMID:
12218091]
J Exp Med. 2006 Jan 23;203(1):131-40
[PMID:
16380513]
Cytokine Growth Factor Rev. 2006 Dec;17(6):451-61
[PMID:
17045835]
J Immunol. 2007 Apr 15;178(8):5312-20
[PMID:
17404316]
Eur J Immunol. 2005 Oct;35(10):2991-3001
[PMID:
16184516]
Int J Colorectal Dis. 2006 Jan;21(1):64-70
[PMID:
15756596]
Shock. 2002 Jun;17(6):463-7
[PMID:
12069181]
Infect Immun. 1996 Aug;64(8):3231-5
[PMID:
8757858]
Infect Immun. 1995 Jun;63(6):2262-8
[PMID:
7768607]
Crit Care Med. 2008 Feb;36(2):482-8
[PMID:
18091546]
Infect Immun. 2006 Jun;74(6):3618-32
[PMID:
16714594]
Nat Rev Immunol. 2004 Jul;4(7):499-511
[PMID:
15229469]
Am J Physiol Regul Integr Comp Physiol. 2005 Oct;289(4):R1048-53
[PMID:
15947070]
J Clin Invest. 2009 Jul;119(7):1921-30
[PMID:
19603547]
J Immunol Methods. 2010 Feb 28;353(1-2):102-10
[PMID:
20006615]
Scand J Trauma Resusc Emerg Med. 2009 Sep 27;17:49
[PMID:
19781105]
J Immunol. 2003 Jan 1;170(1):503-7
[PMID:
12496437]
J Surg Res. 2009 Dec;157(2):235-42
[PMID:
19589542]
